Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Mitsubishi Tanabe to Rebrand as Tanabe Pharma after Bain Takeover
July 2, 2025
-
BUSINESS 17 of 23 Japan Drug Makers Hike Average Pay in FY2024, 7 Firms Break 10-Million-Yen Mark
July 1, 2025
-
REGULATORY MOF Poised to Discuss Use of CEA System with MHLW: Budget Examiner
June 30, 2025
-
REGULATORY Japan Launches Public-Private Council to Create Innovation Ecosystem
June 27, 2025
-
REGULATORY DPP’s Tamura Renews Call to Scrap Off-Year Drug Price Cuts, Urges Protection of On-Patent Prices
June 26, 2025
-
REGULATORY Japan Begins FY2026 Drug Pricing Reform Talks; Responses to Inflation, High-Cost Therapies on Agenda
June 26, 2025
-
REGULATORY Japan Approves MSD’s Airwin/Welireg, J&J Bispecific, and More
June 25, 2025
-
BUSINESS Aculys Moves Toward First Launch as It Tackles Japan’s Drug Lag/Loss
June 24, 2025
-
COMMENTARY Honebuto 2025 Approved - The Real Battle for Pharma Lies Ahead
June 23, 2025
-
ORGANIZATION JGA Targets FY2027 for Resolving Drug Shortages, Two Years Ahead of Forecast
June 20, 2025
-
BUSINESS Will Moderna See Multiple Japan Filings in the Coming Years? 5 Late-Stage Assets in Pipeline
June 19, 2025
-
BUSINESS Taking on Solid Tumors - 6: Pfizer Japan Sees Rosy Uptake with Elrexfio, Mulling Bringing Bispecific Assets for Solid Cancers Too
June 18, 2025
-
ORGANIZATION JMA’s Upper House Candidate Says Scraping Drug Prices to Pool Resources No Longer Holds
June 17, 2025
-
REGULATORY Japan OKs Honebuto Paper with Softened Phrasing on CEA, Sign of Change to Social Security Budgeting
June 16, 2025
-
ORGANIZATION Policy Veterans’ Group Opposes Expansion of CEA Price Adjustments
June 13, 2025
-
BUSINESS AbbVie Japan Looks to Double Sales by 2029 with Rinvoq and Skyrizi as Engines
June 12, 2025
-
BUSINESS Prashant Nikam to Take Over Helm of MSD Japan
June 12, 2025
-
BUSINESS Taking on Solid Tumors - 5: Genmab Pursuing Unique T-Cell Engager Program for Lung Cancer
June 11, 2025
-
BUSINESS Taking on Solid Tumors - 4: With 2 Late-Stage Assets in Wings, Will AstraZeneca Reshape CP Inhibitor Landscape?
June 10, 2025
-
REGULATORY LDP Lawmakers Push Back on Honebuto Draft over CEA, Social Security Budgeting
June 10, 2025
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…